Navigation Links
CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
Date:4/30/2013

garding the long-term outlook for the HeRO Graft product line, PerClot, and revascularization technologies, our belief that we remain well positioned to continue growing our business and leverage our strong cash flow to the benefit of our shareholders, our opportunities and initiatives to expand our market opportunity with higher growth, higher margin products, and our strategy to focus on increasing recurring per procedure handpiece and accessory revenues.  These statements also include our anticipated performance and expected effective income tax rate for 2013.  The risks and uncertainties impacting these statements include that the success of efforts related to any of our product lines, including the HeRO Graft and our handpieces and accessories related to revascularization technologies, is subject to factors beyond our control, including general economic conditions, physician and patient acceptance of our products, our potential inability to maintain reimbursement approvals and maintain and expand reimbursement rates, and regulatory approval.  Competing products may be introduced into the market that may materially impact sales growth for our products.  Integration efforts with respect to newly acquired products may be more costly and take longer than expected.  Our anticipated performance and expected effective income tax rate for the full year of fiscal 2013 is subject to the general risks associated with our business, which, in addition to those discussed above, include that we are significantly dependent on our revenues from BioGlue and are subject to a variety of risks affecting this product, including the risk that BioGlue may be the subject of adverse developments with regard to its safety, efficacy, or reimbursement practices, our BioGlue patent has expired in the U.S., and will expire in the rest of the world in mid-2013, and competitors have obtained FDA approval for indications in which BioGlue has been used off-label and for
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
2. CryoLife Receives FDA Clearance For Next Generation HeRO Device
3. CryoLife Expands Stock Repurchase Program
4. CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
5. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
6. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
7. CryoLife Receives Expanded Indication for BioFoam in Europe
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
10. CryoLife Announces Initiation of Quarterly Cash Dividend
11. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 Array BioPharma,s (NASDAQ: ... this past weekend at the 2015 ESMO World ... At the meeting, data were shared from a ... 100-patient randomized Phase 2 expansion of that trial ... EGFR inhibitor, with or without the addition of ...
(Date:7/6/2015)... 6, 2015 Akcea Therapeutics, a wholly-owned ... ), announced today that the U.S. Food and ... volanesorsen (ISIS-APOCIII Rx ) for the treatment of ... a rare genetic disease characterized by extremely high ... Phase 2 study published in the NEJM in ...
(Date:7/4/2015)... BARCELONA , España, July 4, 2015 /PRNewswire/ ... SIR-Spheres® Y-90 a la quimioterapia de primera línea ... en el hígado (mCRC) extiende la supervivencia libre ... pacientes con cáncer colorrectal metastásico no resecable (mCRC) ... la mayor mejora en la supervivencia libre de ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... February 27 Novagali Pharma, a French,pharmaceutical ... first set of,data pertaining to Nova21027, its ... Novagali communicated about "Ocular ... conventional formulations of prostaglandin,analogues: an in vivo ...
... /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: ... of its new drug application ("NDA") for AFRESA(R), an ultra ... As previously announced, our internal goal was to submit the ... end of February. Based on editorial decisions made during ...
Cached Medicine Technology:Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma 2MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
(Date:7/6/2015)... ... July 06, 2015 , ... ... Medical Spa industries, announces the return of its complimentary educational webinar series ... aesthetic medical business leaders creates success for their clients through targeted marketing, sales, ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ranks ... a particular demographic, however, fat reduction has become more than a way to ...
(Date:7/6/2015)... Vancouver, BC (PRWEB) , ... July 06, 2015 , ... ... has received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department ... Endocrinology is a very exciting field to be practicing in. The technology is changing ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... doTERRA, the ... to its executive management team. Most recently, Jowers held the position as Director of ... years. , After spending a decade building the institute, Jowers states that he was ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN ... same cancer. , “Receiving a cancer diagnosis is often the most traumatic experience ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... AGA Medical Corporation ("AGA,Medical") announced today that it ... and Welfare (MHLW) for its AMPLATZER(R) Duct Occluder ... used for the,non-surgical closure of patent ductus arteriosus ... occurs when a blood vessel known as the ...
... Medical Innovations, Inc. (NYSE: IMA ), a ... solutions, has introduced the pima(TM) analyzer, a ... The initial application of the instrument will be a ... instrument is one of several novel technologies under development ...
... national health care reform a top priority of the ... proposals swirling about Washington, D.C., and around the country, ... stepping up its efforts to identify and launch new ... care delivery systems.With health care reform a central feature ...
... awareness and knowledge of Daiichi Sankyo,s innovative treatmentsPARSIPPANY, N.J., ... it has established a subsidiary -- Daiichi Sankyo de ... Inc. is based in San Juan, and led by ... more than 20 years of experience in pharmaceutical sales ...
... FDA-approved once-daily amoxicillin will be promoted to health ... Pharmaceuticals, Inc. (Nasdaq: MBRK ), today ... extended-release) Tablets, 775mg, will begin on March 16, ... of its 270-person field force which will promote ...
... - Hard to Treat Diseases (HTDS) www.htdsmedical.com ... identified a cosmetics company as a potential merger candidate. ... is engaged in online sales of the "Melem" product. ... It has a wide variety of skin and lip ...
Cached Medicine News:Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 2Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 3Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 2Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 3Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 2Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 3Health News:Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 3Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 4Health News:Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company 2
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
... BD Directigen EZ RSV Test utilizes a new, ... one device for rapid RSV detection. The testing ... method whereby dried reagents have already been applied ... a two-step process, with clear-cut results shown by ...
Medicine Products: